ClinicalTrials.gg
Not yet recruitingNCT07945015MOSAIC-VNSUpdated Nov 18, 2026

Neuromodulation of Sleep and Mood: A Multimodal Biomarker Study of Non-Invasive Vagal Nerve Stimulation (MOSAIC-VNS)

An interventional study of active nVNS and Sham in Insomnia, Major Depressive Diorder and miRNAs, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States — 148 open to participants now, 185 under way, 5 of them phase 3. Sleep Initiation and Maintenance Disorders · United States.

Planned enrollment
535th of 857
40 · median 60
Started
2026
with 60 others
No phase
579 of 905
109 open now
Primary completion
2028-09
later than 150 of 184 live
Registered
903rd of 905
by date

Among the 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States, this one is the 535th largest by planned enrollment of the 857 interventional ones that give a count, is one of 61 that started in 2026, is one of 579 with no phase, reaches primary completion later than 150 of the 184 other live ones, and was the 903rd registered.

Sleep Initiation and Maintenance Disorders

2,730 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

148 of the 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States are open now. Recruiting first, the newest first:

143 more — sign in →

All 148 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 905 studies in Sleep Initiation and Maintenance Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn how non-invasive cervical transcutaneous vagus nerve stimulation (ctVNS) - a treatment given by holding a small hand-held device against the right part of your neck (cervical vagus nerve) - affects sleep, heart rhythm, mood, and certain markers in the blood and some genetic material.

The main questions it aims to answer are:

  1. Will ctVNS enhance both subjective and objective sleep continuity and regularity, improve circadian stability, and increase parasympathetic HRV indices compared with the end-of-sham baseline?
  2. Will improvements in HRV and sleep be associated with greater improvement in standardized depression ratings, with treatment effects mediated in part by improvements in sleep and in part by sleep-independent autonomic mechanisms?
  3. Will ctVNS modify the expression of miRNAs related to sleep, stress, inflammation, and neuroplasticity, and baseline or early-change miRNA profiles, combined with physiological data, and may help distinguish responders from non-responders?

This study lasts about 7 weeks.

Participants will be asked to do the following:

Visit 1/ Baseline (in person):

  • Participants will answer questions about their health, mood, and sleep;
  • have their blood pressure and pulse taken;
  • give about 28 mL (about 6 teaspoons) of blood - 20 mL for the research measurements and 8 mL for routine safety blood tests;
  • be fitted with a wrist device that measures your heart rate, physical activity and sleep; and be given the study device with training on how to use it at home.

This visit will last about 2 hours.

Weeks 1-6 (at home):

  • Participants will use the study device (nerve stimulator) twice a day (morning within 1 hour of waking, and evening within 1 hour of your usual bedtime), each use lasting about 2 minutes;
  • Participants will also need to wear the wrist device day and night;
  • Participants will fill out a short sleep diary each morning.

Visit 2/ Week 2 (in person) and Visit 3/ Week 6 (in person):

  • Participants will repeat the questionnaires and interviews from Visit 1;
  • have their blood pressure and pulse taken;
  • give another blood sample of about 20 mL;
  • have the data from their wrist device downloaded.
  • At each in-person visit after visit 1, their study device will be checked and may be exchanged for another device.

This visit will last about 1.5 - 2 hours.

The investigators will call participants on the phone to check-in at Weeks 1, 3, and 5, and a safety call at Week 7. These phone calls will last about 15 minutes.

Read the detailed description

Major depressive disorder (MDD) and insomnia are highly prevalent, frequently co-occur, and rank among the leading causes of disability worldwide. Up to 80% of people with MDD report significant sleep disturbance, and persistent insomnia predicts higher relapse, poorer treatment response, and greater functional impairment. Autonomic dysregulation, commonly indexed by reduced heart rate variability (HRV), is a shared feature of both conditions and a marker of poor outcome [1], alongside circadian disruption and neuroinflammatory signaling.

Cervical transcutaneous vagus nerve stimulation (ctVNS) engages vagal afferents transcutaneously and may rebalance sympathetic-parasympathetic tone [2,3] and attenuate neuroinflammatory signaling implicated in anxiety and depression [4], with downstream effects on emotion-regulatory circuits and on sleep. Despite this mechanistic plausibility, treatment response to ctVNS remains heterogeneous and mechanistically unclear, and no validated marker identifies who will benefit.

Circulating microRNAs (miRNAs) are stable, accessible post-transcriptional regulators whose peripheral profiles are altered in MDD and may track with diagnosis or relapse risk [5,6]. Preclinical evidence shows that vagus nerve stimulation, which engages the same afferent pathways as ctVNS, modulates stress- and neuroplasticity-related miRNAs (for example, miR-183-3p) [7-9]. Neural-derived exosomes (NDE) isolated from plasma are enriched for signals of neuronal origin and provide a means of interrogating brain-relevant molecular processes from a peripheral blood sample.

Neuromodulation is changing how mental and other central nervous system disorders are treated, but its clinical use is limited by an inability to predict who will respond or why. Three specific gaps slow progress: (1) the pathways linking ctVNS to improvements in sleep and depression remain unclear; (2) no study has combined continuous wearable monitoring with circulating candidate biomarkers to predict response; and (3) the relationship between autonomic change and depression improvement has not been defined.

This study addresses those gaps by combining longitudinal wearable-derived autonomic monitoring, subjective and objective sleep phenotyping, standardized clinical outcomes, and circulating neural-derived exosomal miRNA profiling within a single mechanistic framework. The design separates sleep-mediated from sleep-independent autonomic pathways underlying changes in depression.

A within-subject sham run-in was selected rather than a parallel randomized design because the aim of this pilot is within-subject signal detection and effect-size estimation rather than controlled efficacy testing. The sham run-in establishes a stable, expectancy-adjusted personal baseline and prevents carryover from active stimulation from contaminating that reference. A fixed sham-to-active order partially confounds treatment with time; this limitation is stated explicitly, is mitigated by the end-of-sham anchor and by a group-level autonomic target-engagement check, and is addressed in the planned subsequent randomized, concurrent sham-controlled trial.

Healthy reference participants (Cohort B) are enrolled not as efficacy subjects but to establish normative ranges for HRV, sleep metrics, and candidate miRNA expression, enabling interpretation of disease-related biomarker deviations.

03

Conditions studied

  • Insomnia
  • Major Depressive Diorder
  • miRNAs
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • To be eligible, participants must meet all of the following criteria:

    1. Adults aged 18 through 50 years, inclusive, at the time of consent.
    2. Able to understand and provide written in English.
    3. Willing and able to wear a study-provided wrist-worn device continuously for approximately 6 weeks and to complete daily sleep diaries.
    4. Willing and able to self-administer the study device twice daily for 6 weeks and to complete a device use log.
    5. Access to a smartphone compatible with the study wearable platform, or willingness to use a study-provided device.
    6. Regular sleep opportunity of at least 6 hours per 24-hour period.

      Cohort A (symptomatic) - additional inclusion criteria:

    7. Insomnia Severity Index (ISI) total score ≥ 15 at screening and confirmed at Visit 1.
    8. MADRS total score ≥ 20 at screening and confirmed at Visit 1.
    9. Meets criteria for insomnia disorder on structured clinical interview.
    10. If receiving psychotropic medication or psychotherapy, the regimen has been stable for at least 6 weeks before Visit 1, and the participant and treating clinician agree it will remain stable through Visit 3.

      Cohort B (healthy reference) - additional inclusion criteria:

    11. ISI total score ≤ 7 and MADRS total score ≤ 8 at screening and confirmed at Visit 1.
    12. No current psychiatric disorder or sleep disorder as established by structured diagnostic interview.
    13. No psychotropic medication use within the prior 30 days.

Exclusion criteria

Exclusion Criteria:

  • Participants meeting any of the following criteria are not eligible:

    1. Night-shift or rotating-shift work within the 30 days before Visit 1, or planned during participation.
    2. Travel across more than two time zones within the 14 days before Visit 1, or planned during participation.
    3. Any to cervical nVNS, including an implanted cervical electrical or metallic device, cardiac pacemaker or implantable cardioverter-defibrillator, any other implanted electronic device, carotid atherosclerosis, prior cervical vagotomy, carotid endarterectomy, or cervical surgery at the application site.
    4. Open wound, skin breakdown, active infection, or a dermatologic condition at the intended application site.
    5. Known or suspected pregnancy, or breastfeeding. Participants of will undergo urine pregnancy testing at screening..
    6. Clinically significant cardiac arrhythmia, uncontrolled hypertension (systolic ≥ 160 or diastolic ≥ 100 mmHg on repeated measurement), congestive heart failure, or syncope of unclear cause.
    7. Untreated moderate-to-severe obstructive sleep apnea (STOP-Bang ≥ 5 without evaluation and clearance), restless legs syndrome requiring pharmacologic treatment, narcolepsy, or a circadian rhythm sleep-wake disorder.
    8. Moderate or severe substance or alcohol use disorder within the prior 6 months, or a positive urine drug screen for a non-prescribed substance judged to affect sleep or autonomic measures.
    9. Lifetime diagnosis of bipolar I disorder, schizophrenia, schizoaffective disorder, or another primary psychotic disorder.
    10. Active suicidal ideation with intent or plan (C-SSRS ideation type 4 or 5), any suicide attempt within the prior 6 months, or any clinical presentation requiring urgent or higher-level psychiatric care.
    11. Use of an alternative neuromodulation therapy (implanted VNS, transcranial magnetic stimulation, transcranial direct current stimulation, or electroconvulsive therapy) within the prior 3 months.
    12. Initiation of, or change in dose of, any medication with known substantial effects on heart rate variability (for example, beta-blockers, anticholinergics) within 6 weeks before Visit 1.
    13. Any medical, neurological, or psychiatric condition that, in the investigator's judgment, would compromise participant safety, adherence, or interpretation of study measures.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Sham Run-In (Weeks 1-2)

    Inactive sham stimulation, twice daily. Each participant receives first.

    Device: Sham

  • Active comparator
    Active stimulation (Weeks 3-6)

    Blinded active cervical nVNS, twice daily. Each participant receives second.

    Device: active nVNS

Interventions

  • Deviceactive nVNS

    ctVNS

  • DeviceSham

    sham run-in ctVNS

06

What researchers measure

Primary outcomes

  1. Primary physiologic endpoint as change in parasympathetic heart rate variability (nocturnal RMSSD).

    Linear mixed-effects models estimating within-subject physiologic change from the end-of-sham anchor (week 2), with participant as a random effect and phase, time, cohort, age, sex, and body mass index as fixed effects.

    Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).

  2. Primary clinical endpoint as change in Insomnia Sleep Index (ISI) total score in Cohort A (affected).

    The ISI is a 7-item self-report questionnaire used to assess nature, severity and impact of insomnia over previous 2 weeks. Each item is rated 0-4 , with total score range of 0-28. Higher score indicates greater insomnia severity. Response is defined as ≥ 50% reduction in ISI total score or remission (ISI ≤ 7).

    Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).

Secondary outcomes

  1. Change in Montgomery-Asberg Depression Rating Scale (MADRS) total score in Cohort A (affected) from Visit 2 to Visit 3.

    The MADRS is a 10-item clinician rated scale used to assess severity of depression symptoms. Each item is scored from 0 to 6, with total possible score range of 0-60. A total score of 0-8 indicates no depression, and 8 or above would indicate some level of depression ranging from mild to severe. Higher score indicates greater depression symptoms.

    Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).

  2. Differential expression of neural-derived exosomal microRNAs from Visit 2 to Visit 3.

    Differential expression screening with Benjamini-Hochberg false discovery rate control (q \< 0.05), followed by exploratory penalized regression classifiers with nested cross-validation and reporting of optimism-corrected performance.

    Time frame: Change from Visit 2 (week 2) to Visit 3 (week 6).

07

Study locations

1 site
  • University of Alabama at Birmingham (UAB)
    Birmingham, Alabama 35294, United States
    • Samantha White · Contactswwhite@uabmc.edu · 2059349189
    • Kristine Pike · Contactkristinepike@uabmc.edu · 205-975-8542
    • Matthew Macaluso, DO · Principal investigator
    • Justin Thomas, PhD · Sub investigator
    • Yogesh Dwivedi, PhD · Sub investigator
08

References and documents

Publications

  • Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimise the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res. 2016 Jun;25(3):1057-73. doi: 10.1177/0962280215588241. Epub 2015 Jun 19. PubMed 26092476 ↗
  • Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-291. doi:10.1002/pst.185
  • Ouyang S, Chen W, Zeng G, Lei C, Tian G, Zhu M, Liu Y, Yang M. MicroRNA-183-3p up-regulated by vagus nerve stimulation mitigates chronic systolic heart failure via the reduction of BNIP3L-mediated autophagy. Gene. 2020 Feb 5;726:144136. doi: 10.1016/j.gene.2019.144136. Epub 2019 Oct 17. PubMed 31629817 ↗
  • Xuan Y, Liu S, Li Y, Dong J, Luo J, Liu T, Jin Y, Sun Z. Short-term vagus nerve stimulation reduces myocardial apoptosis by downregulating microRNA-205 in rats with chronic heart failure. Mol Med Rep. 2017 Nov;16(5):5847-5854. doi: 10.3892/mmr.2017.7344. Epub 2017 Aug 23. PubMed 28849082 ↗
  • Bie B, Wang Z, Chen Y, Sheng L, Li H, You H, Ye J, Zhang Q, Li J. Vagus nerve stimulation affects inflammatory response and anti-apoptosis reactions via regulating miR-210 in epilepsy rat model. Neuroreport. 2021 Jun 9;32(9):783-791. doi: 10.1097/WNR.0000000000001655. PubMed 33994524 ↗
  • Zhang HP, Liu XL, Chen JJ, Cheng K, Bai SJ, Zheng P, Zhou CJ, Wang W, Wang HY, Zhong LM, Xie P. Circulating microRNA 134 sheds light on the diagnosis of major depressive disorder. Transl Psychiatry. 2020 Mar 16;10(1):95. doi: 10.1038/s41398-020-0773-2. PubMed 32179735 ↗
  • Li QS, Galbraith D, Morrison RL, Trivedi MH, Drevets WC. Circulating microRNA associated with future relapse status in major depressive disorder. Front Psychiatry. 2022 Aug 17;13:937360. doi: 10.3389/fpsyt.2022.937360. eCollection 2022. PubMed 36061300 ↗
  • Guo B, Zhang M, Hao W, Wang Y, Zhang T, Liu C. Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression. Transl Psychiatry. 2023 Jan 9;13(1):5. doi: 10.1038/s41398-022-02297-y. PubMed 36624089 ↗
  • Lai Y, Zhou X, Guo F, Jin X, Meng G, Zhou L, Chen H, Liu Z, Yu L, Jiang H. Non-invasive transcutaneous vagal nerve stimulation improves myocardial performance in doxorubicin-induced cardiotoxicity. Cardiovasc Res. 2022 Jun 22;118(7):1821-1834. doi: 10.1093/cvr/cvab209. PubMed 34145895 ↗
  • Altinkaya Z, Ozturk L, Buyukguduk I, Yanik H, Yilmaz DD, Yar B, Degirmenci E, Dal U, Veldhuizen MG. Non-invasive vagus nerve stimulation in a hungry state decreases heart rate variability. Physiol Behav. 2023 Jan 1;258:114016. doi: 10.1016/j.physbeh.2022.114016. Epub 2022 Nov 2. PubMed 36334796 ↗
  • Tiwari R, Kumar R, Malik S, Raj T, Kumar P. Analysis of Heart Rate Variability and Implication of Different Factors on Heart Rate Variability. Curr Cardiol Rev. 2021;17(5):e160721189770. doi: 10.2174/1573403X16999201231203854. PubMed 33390146 ↗
  • Yoshino Y, Roy B, Dwivedi Y. Differential and unique patterns of synaptic miRNA expression in dorsolateral prefrontal cortex of depressed subjects. Neuropsychopharmacology. 2021 Apr;46(5):900-910. doi: 10.1038/s41386-020-00861-y. Epub 2020 Sep 12. PubMed 32919404 ↗
  • Ochi S, Roy B, Prall K, Shelton RC, Dwivedi Y. Strong associations of telomere length and mitochondrial copy number with suicidality and abuse history in adolescent depressed individuals. Mol Psychiatry. 2023 Sep;28(9):3920-3929. doi: 10.1038/s41380-023-02263-0. Epub 2023 Sep 21. PubMed 37735501 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Sep 2028, 21 months later.

Of 1,213 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 21 months is above that.

Counting every sponsor, half of 1,291 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Nov 18, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Jan 1, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945015
Responsible party
Matthew Macaluso (Bee McWane Reid Endowed Chair in Mood Disorders, Department of Psychiatry & Behavioral Neurobiology, University of Alabama at Birmingham) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Samantha White
Contact
swwhite@uabmc.edu
205-934-9189
Kristine Pike
Contact
kristinepike@uabmc.edu
205-975-8542
Matthew Macaluso, DO
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion